The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2020 | Future MDS treatment options
Inga Mandac-Smoljanovic
• 5 Mar 2020
Inga Mandac, MD, Clinical Hospital Merkur, Zagreb, Croatia, discusses future priorities to focus on combinational treatments with targeted agents or monoclonal antibodies for myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
